Join
Live feed
·
INSIDERFilingvia Quantisnow
Rapport Therapeutics Inc. logo

Chief Scientific Officer Bredt David sold $197,338 worth of shares (6,567 units at $30.05) and gave a grant of 18,000 shares, decreasing direct ownership by 6% to 404,075 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
RAPP· Rapport Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track RAPP (Rapport Therapeutics Inc.) and more on Quantisnow.

Chief Scientific Officer Bredt David sold $197,338 worth of shares (6,567 units at $30.05) and gave a grant of 18,000 shares, decreasing direct ownership by 6% to 404,075 units (SEC Form 4) | Quantisnow